10-Q
MEDICINES CO /DE filed this form 10-Q on 15 May 2002
- velhartice.info
<PAGE>
                                                                              14


            either Party, the non-bankrupt Party shall further be entitled to a
            complete duplicate of (or complete access to, as appropriate) any
            such intellectual property, and such, if not already in its
            possession, shall be promptly delivered to the non-bankrupt Party,
            unless the bankrupt Party elects to continue, and continues, to
            perform all of its obligations under this Agreement.

3.          DEVELOPMENT AND COMMERCIALIZATION

3.1.        Transfer of ASTRAZENECA Know-How. Without unreasonable delay
            following the License Agreement Effective Date, ASTRAZENECA shall
            make available and transfer to TMC the following ASTRAZENECA
            Know-How.

            a)    a description of the process used by ASTRAZENECA for the
                  manufacturing of the Compound intended for Phase III Clinical
                  Trials and a summary report of the development of such
                  process;

            b)    a description of the process, available to AstraZeneca at the
                  License Agreement Effective Date, for the manufacture of the
                  [**] to be used for the manufacturing of the Compound;

            c)    a description of the analytical methods and validation reports
                  for the starting materials and intermediates to be used in the
                  manufacturing of the Compound.

                  It is acknowledged that at the License Agreement Effective
                  Date some of those analytical methods are not fully developed
                  and validated, and such development and validation will not be
                  continued or completed by ASTRAZENECA. ASTRAZENECA